Welcome to our dedicated page for BioPlus Acquisition news (Ticker: BIOSW), a resource for investors and traders seeking the latest updates and insights on BioPlus Acquisition stock.
BioPlus Acquisition Corp. (BIOSW) is a company focused on effecting mergers, capital stock exchanges, asset acquisitions, and reorganizations within the healthcare industry across the U.S., EU, Israel, and Australasia. It recently announced the termination of a business combination agreement and plans to liquidate, intending to return funds to shareholders. BIOSW expects to redeem all public shares for an estimated price per share and dissolve in accordance with its Charter. The company sponsor has waived redemption rights for certain shares, and there will be no liquidating distributions for warrants.
BioPlus Acquisition Corp. announced the pricing of its upsized initial public offering (IPO) of 20 million units at $10.00 each. The units will begin trading on Nasdaq on December 3, 2021, under the ticker symbol BIOSU. Each unit comprises one Class A share and one-half of a redeemable warrant, which allows the purchase of one Class A share at $11.50. The securities will eventually trade separately under BIOS for shares and BIOSW for warrants. The company focuses on the life sciences sector for its business combinations.
BioPlus Acquisition Corp. announced the pricing of its upsized initial public offering (IPO) of 20 million units at $10.00 per unit, set to trade on Nasdaq under the symbol BIOSU starting December 3, 2021. Each unit includes one Class A ordinary share and one-half of a redeemable warrant, with each whole warrant allowing the purchase of one share at $11.50. The company aims to pursue mergers or acquisitions primarily within the life sciences sector, with Cantor Fitzgerald & Co. as the sole book-running manager for this offering.
FAQ
What is BioPlus Acquisition Corp. focused on?
What recent announcement did BioPlus Acquisition Corp. make?
What is the estimated redemption price per share for public shares?
What rights does the company sponsor waive with respect to certain shares?
Will there be liquidating distributions for warrants?
